Business
Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors
- Heidi Hunter, accomplished healthcare leader and President of Cardinal Health Specialty Solutions, to bring additional global biopharma strategic and
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"- Heidi Hunter, accomplished healthcare leader and President of Cardinal Health Specialty Solutions, to bring additional global biopharma strategic and operational expertise to Sutro's Board -\n\n\nSOUTH SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Heidi Hunter has been appointed to Sutro's Board of Directors.\n\"Heidi is an accomplished leader with considerable experience driving the successful development and commercialization of new medicines,\" said Bill Newell, Chief Executive Officer of Sutro. \"We are delighted to have her join our Board as we continue to advance STRO-001 and STRO-002 through the clinic.\" \nConnie Matsui, Chair of Sutro's Board of Directors commented, \"Heidi brings a breadth of valued expertise to the Sutro Board as the company is making substantial effort to accelerate the development of innovative treatments for cancer patients.\"\nHeidi Hunter has over 25 years of experience in biotech across the pharmaceutical value chain, from clinical and commercial development through to launch execution. She is currently President at Cardinal Health, where she leads the Specialty Solutions Business. Prior to Cardinal Health, Ms. Hunter was Senior Vice President of the Global Immunology Business Unit at UCB in Brussels. She has also held leadership positions at Boehringer Ingelheim as Senior Vice President and General Manager in its Global Biosimilars Business, and at IQVIA as Vice President of Global Business Partnerships Commercial Solutions. Ms. Hunter also held senior leadership positions in commercial and strategic marketing for biologics and oncology at Centocor, a J&J company. She also led oncology business at Wyeth (today part of Pfizer) in the U.S. and Novo Nordisk in Denmark. Early in Ms. Hunter's career, she led sales and marketing at Ciba-Geigy in Switzerland (today part of Novartis). She is currently on the board of Vicore Pharma. Ms. Hunter earned B.A. from The University of Michigan and her M.B.A. from The University of Chicago. \nAbout Sutro Biopharma Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug di...